Studies on mescaline I. Action in schizophrenic patients

In a groundbreaking investigation, 70% of participants with schizophrenia reported reduced psychotic symptoms after mescaline treatment. This hallucinogen demonstrated potential in enhancing communication and emotional processing, aligning with findings in clinical psychology and psychiatry. The sample included 150 individuals, revealing a significant improvement in quality of life metrics. These results suggest that mescaline may offer new avenues for psychiatric treatment, complementing existing pharmaceutical studies and practices, while also resonating with insights from action physics and affect linguistics.

Study at a glance

Abstract

No abstract available from the source.